Sabizabulin, an oral, first-in-class alpha and beta tubulin inhibitor/cytoskeleton disruptor small molecule for the treatment of metastatic castration resistant and androgen receptor targeting agent resistant prostate cancer. Sabizabulin – Oral, targeted α & β tubulin inhibitor In Development for Castration Resistant Metastatic Prostate Cancer (mCRPC) Sabizabulin – mechanism of action against prostate cancer MIAMI | LONDON | MALAYSIA © 2021 Veru Inc. | All Rights Reserved | Accreditation and Certificates | Privacy Policy | Anti-Trafficking Policy | Terms of Use | Contact Us Website Design by Get Sharp, Inc.